Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 12, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NDA filing for Breakthrough Therapy designated AXS-05 in MDD expected in 4Q 2020 NDA filing for AXS-07 in migraine expected in 4Q 2020 Topline results for STRIDE-1 Phase 3 trial of AXS-05 in TRD on...
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
March 05, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
March 04, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, March 12, 2020 at 8:00 AM Eastern Time NEW YORK, March 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 13, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...